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INTRODUCTION 
PHARMACEUTICAL ANALYSIS: 
Pharmaceutical analysis may be defined as a process or a sequence of 
process to identify and or quantify a substance or drug, the components of a 
Pharmaceutical solution or mixture or the determination of the structure  of 
chemical compounds used in the formulation of Pharmaceutical product.
1
 
CLASSIFICATION: 
Pharmaceutical analysis can be classified in the various ways  
All pharmaceutical analysis process can be categorized into two groups:  
1. Qualitative (Identification) 
2. Quantitative (Estimation) 
1) Qualitative analysis: the analysis of a substance in order to ascertain 
the nature of its chemical constituents. It is mainly used in the 
determination of assay of samples. 
2) Quantitative analysis: Chemical analysis designed to determine the 
amount or proportion of the components of a substance. It is mainly 
used in the degradation studies to determine the amount of drug and 
degraded products present in the sample.
2
 
Various types of qualitative analysis: 
1) Chemical Methods      
a. Volumetric or Titrimetric Methods  
b. Gravimetric Methods 
c. Gasometric Analysis 
2) Electrical Methods 
3) Instrument Methods 
4) Biological and Microbiological.  
Introduction 
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DEGRADATION STUDIES: 
Forced degradation studies are also known as stress testing, stress 
studies, stress decomposition studies, forced decomposition studies, etc. 
Forced degradation is a process that involves degradation of drug products 
and drug substances at conditions more severe than accelerated conditions and 
thus generates degradation products that can be studied to determine the 
stability of the molecule. The ICH guideline states that stress testing is 
intended to identify the likely degradation products which further helps in 
determination of the intrinsic stability of the molecule and establishing 
degradation pathways, and to validate the stability indicating procedures used. 
But these guidelines are very general in conduct of forced degradation and do 
not provide details about the practical approach towards stress testing. 
3
 
Although forced degradation studies area regulatory requirement and 
scientific necessity during drug development, it is not considered as a 
requirement for formal stability program. It has become mandatory to perform 
stability studies of new drug moiety before filing in registration dossie r. The 
FDA and ICH guidance’s state the requirement of stability testing data to 
understand how the quality of a drug substance and drug product changes with 
time under the influence of various environmental factors. The stability 
studies include long term studies (12months) and accelerated stability studies 
(6months).But intermediate studies (6months) can be performed at conditions 
milder than that used in accelerated studies. So the study of degradation 
products like separation, identification and quantitation would take even more 
time.  
2. OBJECTIVE OF FORCED DEGRADATION STUDIES: 
Forced degradation studies are carried out to achieve the following purposes: 
1) To establish degradation pathways of drug substances and drug 
products. 
2) To differentiate degradation products that is related to drug products 
from those that are generated from non-drug product in a formulation. 
Introduction 
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3) To elucidate the structure of degradation products,  
4) To determine the intrinsic stability of a drug substance in formulation.  
5) To reveal the degradation mechanisms such as hydrolysis, oxidation, 
thermolysis or photolysis of the drug substance and drug product 
6) To establish stability indicating nature of a developed method.  
7) To understand the chemical properties of drug molecules.  
8) To generate more stable formulations. 
9) To produce a degradation profile similar to that of what would be 
observed in a formal stability study under ICH conditions.  
10) To solve stability-related problems4, 5 
Forced degradation performed:  
It is very important to know when to perform forced degradation 
studies for the development of new drug substance and new drug product. 
FDA guidance states that stress testing should be performed in phase III of 
regulatory submission process. Stress studies should be done in different pH 
solutions, in the presence of oxygen and light, and at elevated temperatures 
and humidity levels to determine the stability of the drug substance.  
These stress studies are conducted on a single batch. The results should 
be summarized and submitted in an annual report. However, starting stress 
testing early in preclinical phase or phase I of clinical trials is highly 
encouraged and should be conducted on drug substance to obtain sufficient 
time for identifying degradation products and structure elucidation as well as  
optimizing the stress conditions. An early stress study also gives timely 
recommendations for making improvements in the manufacturing process and 
proper selection of stability-indicating analytical procedures.
6, 7 
Degradation of drug substances between 5% and 20% has been 
accepted as reasonable for validation of chromatographic assays
8
. Some 
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pharmaceutical scientists think 10% degradation is optimal for use in 
Analytical validation for small pharmaceutical molecules for which 
acceptable stability limits of 90% of label claim is common
9
. Others 
suggested that drug substance spiked with a mixture of known degradation 
products can be used to challenge the methods employed for monitoring 
stability of drug product. No such limits for physiochemical changes, los s of 
activity or degradation during shelf life have been established for individual 
types or groups of biological products 
10, 11
. 
 It is not necessary that forced degradation would result in a 
degradation product. The study can be terminated if no degradation is seen 
after drug substance or drug product has been exposed to stress conditions 
than those conditions mentioned in an accelerated stability protocol 
12
. This is 
indicative of the stability of the molecule under test. Over-stressing a sample 
may lead to the formation of a secondary degradation product that would not 
be seen in formal shelf-life stability studies and under-stressing may not 
generate sufficient degradation products 
13
. Protocols for generation of 
product-related degradation may differ for drug substance and drug product 
due to differences in matrices and concentrations. It is recommended that 
maximum of 14 days for stress testing in solution (a maximum of 24h for 
oxidative tests) to provide stressed samples for methods development.
14 
IMPURITY PROFILING 
The definition of the impurity profile of a new drug material as given 
in the guidelines of ICH is “A description of the identified and unidentified 
impurities, present in a new drug substance”. As for impurity profiling, it is 
the common name attributed to analytical activities performed with the aim of 
detecting, identifying or elucidating the structure and quantitatively 
determining and inorganic impurities as well as residual solvents in bulk and 
pharmaceutical formulation. 
If the impurities of a drug material (the difference between 100% and 
the 98-99% mentioned above) are physiologically highly active (toxic) 
materials, in principle they could contribute to the side effect profile of the 
Introduction 
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drug .since the impurity profile of a drug material depend on the synthesis 
route and other factors, this could make the side –effect profile 
irreproducible, adversely influencing the safety of the drug therapy. By 
estimating the impurity of a drug material and setting strict limits for the 
impurities, this danger can be minimized.
15
 
1.1. TYPES OF STABILITY STUDIES 
There are three types of stability studies, which give an idea about the 
stability of drugs. 
A. Long term stability studies 
B. Accelerated stability studies and 
C. Intermediate testing: 
Long term stability testing (Real Time Testing):  
The length of the studies and the storage conditions should be 
sufficient to cover storage, shipment and subsequent use Temperature 
sensitive drug substances should be stored under an alternative lower 
temperature condition, which will then become the designated long term 
testing storage temperature. Storage for long term testing- 25°C ± 2°C/ 60 % 
RH ± 5 % RH, minimum time Period for submission 12 months .  
Accelerated stability testing: 
To introduce new products into the market or for making material 
changes in the process, formula, or container closure system of existing 
products one cannot wait until all the needed stability data at room 
temperature are generated. These studies are designed to increase the rate o f 
chemical degradation or physical change of an active drug substance or drug 
product by using exaggerated storage conditions as part of the formal, 
definitive storage program. Results from accelerated testing studies are not 
always indicative of physical change. Storage condition for accelerated 
testing 40°C ± 2°C/ 75 % RH ± 5 % RH, minimum time period for submission 
6 months  
Introduction 
College of Pharmacy, MMC, Chennai-3. Page No.6 
Intermediate testing:  
Intermediate studies are conducted at 30°C/65% RH and designed to 
moderately increase the rate of chemical degradation or physical changes for 
a drug substance intended to be stored long term at 25°C Generally these 
studies are conducted when the accelerated studies for General Case (40°C/75 
% RH) failed to meet the acceptance criteria.
16
 
Table-1 Conditions used for force degradation studies 
17 
Solid state 
Stress Condition Period of time 
Heat 60°C 1month 
Humidity 75°C 1 month 
Photo stability Exposed And Non Exposed 
Sample (Control) 
Follow ICH 
requirements 
Solution state 
Stress Condition Period of time 
hydrolysis Acid 0.1-1 Mol L-1 HCl Up to weeks and 60ºC 
Alkali 0.1-1 Mol L-1 NaOH Up to weeks and 60ºC 
Oxidation 3% (v/v)H2O2  Up to 24HOURS 
Photo stability Exposed and non-exposed  
sample (Control) 
Follow ICH 
requirements 
Heat 60ºC Up to 1 month 
CHARACTERISATION OF DEGRADADED PRODUCTS 
The characters of the degraded fragments were studied by both 
spectrophotometric methods and chromatographic techniques. The degraded 
products were analyzed by following methods. 
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No Degradation 
Sufficient 
Degradation 
Sufficient 
Degradation 
START 
DEGRADATION USING 0.1MNaOH/0.1MHCl/5%H2O2 
ACCEPT 
1MNaOH/HCl / 
10% H2O2 
2MNaOH/HCl / 
20% H2O 2 
5MNaOH/HCl/ 
40%H2O2 
PRACTICALLY 
STABLE 
0.01MNaOH/HCl/ 
3%H2O2 
CARRY OUT 
UNDER MILD 
CONDITIONS 
No Degradation Total Degradation 
No Degradation 
UV SPECTROSCOPY 
INFRA RED SPCTROSCOPY 
UHPLC 
These methods were used to determine the assay and the amount of 
sample present in the degraded products and also used in identification of 
impurities  
SCHEME OF FORCED DEGRADATION 
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DRUG PROFILE 
DRUG NAME PYRAZINAMIDE 
BRAND NAME Pyzina-1000mg 
IUPAC NAME Pyrazine-2-carboxamide 
MOLECULAR 
NAME 
C5H5N3O 
MOLECULAR 
WEIGHT 
123.1g/mol. 
CAS NUMBER 98-96-4 
CHEMICAL 
STRUCTURE 
N
NH2N
O
 
BASIC MOIETY Pyrazine nucleus 
CATEGORY First line drug, Antitubercular agent 
DESCRIPTION white or almost white crystalline powder odorless or 
almost  Odorless 
SOLUBILITY It is soluble in water and in chloroform; slightly 
soluble in ethanol 95% and slightly soluble in ether. 
18
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MECHANISM OF ACTION 
Pyrazinamide is a prodrug that stops the growth of mycobacte rium 
tuberculosis. Pyrazinamide diffuses into the granuloma of mycobacterium 
tuberculosis, where the enzyme Pyrazinamidase converts Pyrazinamide to the 
active form pyrazinoic acid under acidic conditions, the pyrazinoic acid that 
slowly leaks out converts to the protonated conjugate acid which is thought to 
diffuse easily back into the bacilli and accumulate the net effects that more 
pyrazinoic acid accumulates inside the bacillus at acid pH than neutral pH.
19
 
 
Pyrazinoic acid was thought to inhibit the enzyme fatty acid synthase 
(FAS) in, which is required by the bacterium to synthesise fatty acids 
although this has been discounted. 
DRUG INTERACTIONS: Pyrazinamide Interactions gout, 
hepatotoxicity, liver diseases renal dysfunction, diabetes mellitus, 
hemodialysis 
PREGNANCY: Pyrazinamide only recommended during pregnancy 
when benefit outweighs risk. 
NURSING MOTHERS: Pyrazinamide is excreted into human milk in 
small amounts. The manufacturer recommends that caution be used when 
administering pyrazinamide to nursing women. 
Introduction 
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SIDE EFFECTS: Pain in large and small joints, loss of appetite, pain 
and swelling of joints, especially big toe ankle and knee, unusual tiredness or 
weakness yellow eye or skin rarely producing itching, skin rash.  
DOSING: Recommended drugs for the initial treatment of tuberculosis 
in children and adults daily dose=15mgto30mg/kg  po (per orally),A single 
1000mg dose may used for tuberculosis,3 grams per day should not exceed, 
2gm per day when given as daily regimen 
It is administered orally.  
INDICATIONS: 
Pyrazinamide is used to treat tuberculosis (TB).It is an antibiotic and 
works by stopping the growth of bacteria. This antibiotic treats only bacterial 
infections
20
. 
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REVIEW OF LITERATURE 
1) Abdel et al.,(2015) reported a development and validation of a 
quantitative and a stability –indicating densitometric method for 
sensitive estimation of some active TB drugs, As the stationary phase  
and the eluent comprised two mobile phase were selected. Chloroform-
ethanol isopropanol (4.5:5.25:5.25v/v/v)and ethanol –chloroform-
ammonia (33%) 7:7:0.5 v/v/v) densitometric analysis was achieved at 
λmax270nm for rifampicin isoniazid and pyrazinamide stress was 
carried by under acid base oxidation and photolytic degradation.
21
 
2) Drashti Desai, Megha Shah. (2015) a review article on validated 
analytical methods developed on Antitubercular Drug, Rifampicin. The 
clinical and pharmaceutical analysis of this drug requires effective 
analytical procedures for quality control and pharmacodynamics and 
pharmacokinetic studies as well as stability study. An extensive survey 
of the literature published in various analytical and pharmaceutical 
chemistry related journals has been conducted and the instrumental 
analytical methods which were developed and used for determination 
of Rifampicin as single or combination with other drugs in bulk drugs, 
formulations and biological fluids have been reviewed .22  
3) Blessy M et al., (2014) a review article on development of forced 
degradation and stability indicating of drugs. Forced degradation is a 
degradation of new drug substance and drug product at conditions more 
severe than accelerated conditions. It is required to demonstrate 
specificity of stability indicating methods and also provides an insight 
into degradation pathways and degradation products of the drug 
substance and helps in elucidation of the structure of the degradation 
products. Forced degradation studies show the chemical behavior of 
the molecule which in turn helps in the development of formulation 
and package.
23
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4) Nerdy et al., (2014) evaluated high performance liquid 
chromatography mass spectrometry method to analyze a mixture of 
rifampicin, isoniazid and pyrazinamide. C18 column as stationary  
phase  and  mass  spectrometry  as  a  detector  in  selected  ion  
monitoring  mode.
24
 
5) Paolo miotto et al.,(2014) reported a Mycobacterium tuberculosis 
pyrazinamide resistance determinants: Multicenter study, Pyrazinamide 
is a prodrug that is converted to pyrazinoic acid by the enzyme 
Pyrazinamide, encoded by the pncAgene in mycobacterium 
tuberculosis.
25
 
6) M.S. Charade et al., (2013) a review article on forced degradation 
studies of new drug substances and drug products are important to help 
develop and demonstrate specificity of stability-indicating methods and 
to determine the degradation pathways and degradation products of the 
active ingredients. Conventional methods (e.g. Column chromatography) 
or hyphenated techniques (e.g.LC MS, LCN MR)can be used to 
identification and characterization of the degradation products.
26
 
7) Abdel Maaboud et al., (2013) developed a simple and sensitive method 
for determination of ethambutol (EMB), isoniazid (INH), pyrazinamide 
(PZA) and rifampicin (RIF) in pure and pharmaceutical dosage forms. 
The method is based on measuring the quenching effect of studied 
drugs on the fluorescence intensity of NBS-phenothiazine oxidation 
product (NBS-Phz) in a buffered medium (pH 7, λex 271 and λem 375 
nm). Different factors affecting the reaction were studied and 
optimized. Under the optimized conditions, linear relationships with 
good correlation coefficients (0.9995-0.9999) were obtained. The 
limits of detection were 0.139, 6.39 x 10
-3
, 0.029 and 0.180 µg ml
-1
 for 
EMB, INH, PZA and RIF respectively.
27
 
8) Kishore Kumar Hotha et al., (2013) a review article to give a detailed 
description of the forced degradation studies as per the regulatory 
guidelines that are associated with various regulatory agencies. This 
Review of Literature 
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article summarizes the collective views of industry practices on the 
topic of forced degradation studies. The article includes an overview of 
existing guidance’s and literature for best practices .28 
9) Ganga Prasad chenna et al., (2011) reported a simple, precise, 
specific and accurate Reverse phase HPLC method has been developed 
for the determination of Pyrazinamide in bulk and pharmaceutical 
dosage forms. C8 (4.6 x 250mm, 3.5 μm) column with Phosphate 
buffer (pH 4.4): Methanol 80:20 (v/v) as a mobile phase at a flow rate 
of 1 ml/ min. Detection was performed at 269 nm. The retention time 
of Pyrazinamide was found to be 3.62min. By Adoption of this 
procedure Pyrazinamide (PYZ) is eluted completely.
29
 
10) 10. Ganga Prasad chenna et al., (2011) reported, two simple, accurate 
and precise spectrophotometric methods have been developed for 
Pyrazinamide in bulk and pharmaceutical dosage form. Pyrazinamide 
has absorbance maxima at 269nm.Method A is area under curve (AUC) 
method, which involves the calculation of integrated value of 
absorbance with respect to wavelength between 264-274nm. Method B 
involves the derivatisation of the primary absorption spectra to second 
order and by the examination of the second derivative spectra of 
Pyrazinamide, 270 nm (λ) was selected as working wavelength. 30 
11) Saranjit Singh et al., (2010) reported the extent of degradation of 
rifampicin, isoniazid and pyrazinamide from prepared mixture and 
marketed preparation containing single ,two,three,and four, drugs 
under stomach conditions degradation studies carried out in 0.1M HCL 
at 37 ºC for 50mins. A comparative study in stimulated gastric fluid 
was also done. Under both conditions rifampicin was decomposed by 
(17.8-24.4%), isoniazid to a lesser extent (3.2-4.7%) and pyrazinamide 
was stable.
 31
 
12) S.K.Dhal et al. (2009) reported a new reversed –phase HPLC method 
for the simultaneous analysis of pyridoxine Hcl, Isoniazid, 
Pyrazinamide, and Rifampicin in a tablet formulation has been 
Review of Literature 
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developed. This method is accurate, reproducible, repeatable, linear, 
precise, selective, and thus reliable. The run time was relatively short, 
i.e.20min.
32
 
13) M. Y. Khuhawar et al., (2005) reported a simple HPLC method for 
determination INH, PZA, and IM in pharmaceutical preparations. Pre-
column derivatization with MFA is used for INH. Isocratic elution 
from a reversed-phase ODS column results in ng per injection 
detection limits. Analysis of the drugs resulted in CV of 0.54–0.74% 
with relative deviation up to 4.8%. 
33
 
14) John E.et al., (2000) investigated the measurement of pyrazinamide in 
human plasma, bronchoalveolar lavage and alveolar cells by reversed 
phase column chromatography.
34
 
15) A.Brouard et al., (1985) reported a gas chromatographic-mass 
spectrometric technique and published a high-performance liquid 
chromatographic (HPLC) technique that had a very long and difficult 
extraction. The present method involves reversed-phase HPLC with 
UV detection of pyrazinamide.
35
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AIM AND OBJECTIVE 
The aim of the study is to develop simple, novel methods for the forced 
degradation of Pyrazinamide in Bulk and Formulation. The quantification of 
Pyrazinamide have been reported and review of literature indicated that no 
degradation studies have been reported for pharmaceutical formulation till 
date 
The objective of the present work is develop various analytical 
methods such as 
 UV -SPECTROPHOTOMETRY 
 INFRA RED SPECTROPHOTOMETRY 
 UHPLC METHODS 
The study includes the following: 
 To perform the acid and alkali hydrolysis, oxidative degradation, 
thermal and Photolytic degradation.  
 Quantification of degraded product by UV and UHPLC.  
 Comparing the results of bulk and sample with standard.  
 Identification of changes in functional group present in the degraded 
samples by IR 
Materials and Methods 
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MATERIALS AND METHODS 
DRUG SAMPLES AND STUDY PRODUCTS 
Pyrazinamide Standard was obtained from Micro Labs in Hosur  
TEST PRODUCT  
Pyrazinamide tablets (Pyzina -1000mg) were purchased from medical 
shop. 
CHEMICALS AND SOLVENTS USED FOR DEGRADATION 
Hydrochloric Acid Merck, AR Grade, Mumbai, India. 
Hydrogen Peroxide  (5%W/V) Merck, AR Grade ,Mumbai ,India 
Sodium hydroxide Merck, AR Grade ,Mumbai ,India 
Chloroform Merck, AR Grade ,Mumbai ,India 
Ethanol Merck, AR Grade ,Mumbai ,India 
Methanol Merck, HPLC Grade ,Mumbai ,India 
Acetonitrile Merck, HPLC Grade ,Mumbai ,India 
Water Double Distilled 
INSTRUMENTS USED: 
Shimadzu V-630 UV Spectrophotometer Double beam, UV Probe 2.31  
Rankem-IR, KBr Press Cary 630 FTIR 
Agilent UHPLC Infinity 1220 LC, UV Detector 
Electronic Balance Wensar, PGB-200 
FORCED DEGRADATION 
Forced degradation studies are used to identify reactions which may 
occur to degrade a processed product. Usually conducted before final 
formulation, forced degradation uses external stresses to rapidly screen 
material stabilities. Forced degradation is a process that involves degradation 
of drug products and drug substances at conditions more severe than 
Materials and Methods 
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accelerated conditions and thus generates degradation products that can be 
studied to determine the stability of the molecule.
36 
ANALYTICAL PROCEDURES 
Degraded samples were analyzed using spectrophotometric methods 
like UV, IR and chromatographic methods like UHPLC.The assays of 
degraded samples were carried out by UV and UHPLC and the changes in the 
functional group of drug were detected by IR spectroscopy.  
HYDROLYTIC DEGRADATION 
Hydrolysis usually means the cleavage of chemical bond by the 
addition of water. The main source of impurities in the formulation is for 
hydrolytic degradation. Water either as a solvent or a moisture in the air 
comes in contact with pharmaceutical dosage form is responsible for 
degradation of most of the drugs.  In hydrolytic study under acid and basic 
condition, pyrazinoic acid is cleaved from pyrazinamide in 0.1M NaOH and 
0.1M HCl are employed for generating acidic and basic stress samples 
respectively. If sufficient degradation is not observed, higher strength are 
employed to induce degradation (1M NaOH/1M HCl)
 
 
OXIDATIVE DEGRADATION 
The increase in oxidation state of an atom through a chemical reaction 
is known as an Oxidation. Most of the drug undergoes auto oxidation because 
of oxygen in air. Therefore it is an important degradation pathway of many 
drugs. Auto oxidation is a free radical reaction that requires free radical 
initiator to begin the chain reaction. Hydrogen peroxide, metal ions in a drug 
substance act as initiator for auto oxidation. Hydrogen peroxide is a common 
oxidant to produce oxidative degradation products which may arise as minor 
impurities during long term stability studies. Hydrogen peroxide seems to be 
much more popular for the purpose than any other oxidizing agent. The 
strength of H2O2 used varies from 1% to 30%.in some drugs extensive 
degradation is seen when exposed to 3% H2O2 for very short time periods at 
room temperature in other cases, exposure to high concentration of  H 2O2 
even under extreme conditions does not cause  any significant degradation. 
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The behavior is on expected lines, as some drugs are in fact or disable, while 
there are others that are not. The latter are not expected to show any change 
even in the presence of high dose of oxidizing agents.  
THERMAL DEGRADATION 
Temperature also plays a role in degradation of drugs.  High 
temperature leads to increase in degradation of drugs.  Most of the drugs are 
sensitive to temperature. Thermal degradation can cause reactions like 
pyrolysis, hydrolysis, decarboxylation isomerization rearrangement and 
polymerization 
PHOTOLYTIC DEGRADATION  
Exposure of sun light to drug is called photolytic degradation. The rate 
of degradation is directly proportional to the intensity; quantity of sun light 
absorbed by the drug. It is carried out by exposing the drug substance and 
drug product to a sun light. (ICH Guidelines) 
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UV SPECTROSCOPY 
UV refers to absorption spectroscopy, spectroscopy in the ultra violet 
spectral region .this means it uses light in the visible and adjacent (near -UV 
and near –infrared (NIR)) ranges. The absorption in the visible range directly 
affects the perceived color of the chemicals involved. In this region of the 
electromagnetic spectrum, molecules undergo electronic transitions. 
molecules containing  -electrons or non-bonding electron ( -electrons) can 
absorb the energy in the form of ultraviolet or visible light to excite these 
electron the longer the wavelength of light it can absorb.  
In degradation studies UV plays one of the roles in detection of 
impurities assay values of drug products can be calculated using 
spectroscopy. In ultra violet region every molecule will give its own 
absorption at particular wavelength this is called  max. Every compound has 
unique   max and absorption. Absorption values vary only with the 
concentration of the compound. Degraded samples spectrum can be compared 
with standard spectrum to identify the degradation .After degradation the 
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absorption and the  max of the samples can vary from the standard. This 
shows the degradation of samples
38
. 
Materials and Methods 
All absorption spectrum were measured by Shimadzu V-630 UV 
Spectrophotomer with 1cm matched quartz cells. 
Reagents used 
0.1M Sodium hydroxide  
0.1M Hydrochloric acid 
5% Hydrogen peroxide 
Acetonitrile 
Distilled water 
PREPARATION OF REAGENTS 
Preparation of 0.1M Sodium hydroxide 
4 gm of Sodium hydroxide pellets were weighed and dissolved in small 
amount of distilled water then made up the volume to 1000ml  
Preparation of 0.1M Hydrochloric acid 
8.33ml of concentrated hydrochloric acid was measured and diluted  
with distilled water to 1000ml 
Preparation of 5% Hydrogen peroxide: 
50ml of Hydrogen peroxide was diluted with distilled water and the 
volume made up to1000ml 
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Table-2 Intraday scheme UV –study of Bulk and Formulation  
Degradation 
Type 
Experimental 
Conditions 
Storage 
Conditions 
Sampling 
Time 
 Control sample  Room temperature  30,60,90 mins 
Hydrolysis 0.1M NaOH Room temperature  30,60,90mins 
0.1M HCl Room temperature  30,60,90mins 
Acid control Room temperature  30,60,90mins 
Base control Room temperature  30,60,90mins 
Oxidation 5% H2O2(control) Room temperature 30,60,90mins 
5% H2O2  Room temperature 30,60,90mins 
 
Table-3 Inter day scheme UV –study of Bulk and Formulation  
 
Degradation 
Type 
Experimental 
conditions 
Storage 
conditions 
Sampling 
time 
 Control sample  Room temperature  1,3,5 days 
Hydrolysis 0.1M NaOH Room temperature  1,3,5 days  
0.1M HCl Room temperature  1,3,5 days 
Acid control Room temperature  1,3,5 days 
Base control Room temperature  1,3,5 days 
Oxidation 5% H2O2  (control) Room temperature 1,3,5 days 
5% H2O2  1,3,5 days 
Thermal Heating chamber 50ºc  1,3,5 days 
Photolytic  Sunlight  1,3,5 days 
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INTRADAY STUDY OF HYDROLYTIC DEGRADATION USING 
0.1M NaOH 
Standard Preparation 
100mg Pyrazinamide was transferred to volumetric flask and dissolved 
in 100ml of distilled water to achieve a concentration of 1mg/ml. The solution 
was kept at room temperature. An aliquot solution was then diluted with 
distilled water to get final concentration of 10µg/ml. The solution was 
scanned in the UV region and the maximum absorbance was recorded at 
270nm. 
System suitability solution: Transfer of 1ml hydrochloric acid to 
volumetric flask, dilute with standard preparation to volume mix. Keep the 
solution on a boiling water bath for 5 minutes and cool. (1:4)  
Bulk preparation (Stress) 
100mg of Pyrazinamide bulk was weighed and transferred to 
volumetric flask, dissolved 0.1M NaOH to produce 1mg/ml. The solution was 
kept at room temperature. After 30mins, an aliquot solution was diluted with 
distilled water to get final concentration of 10µg/ml. The solution was 
scanned in the UV region and the maximum absorbance was recorded at 
270nm.The same procedure was repeated for 60min and 90min time interval.  
Sample preparation (stress) 
100mg equivalent of Pyrazinamide tablets were crushed weighed and 
transferred to volumetric flask, dissolved in 0.1 M NaOH to achieve a 
concentration of 1mg /ml. The solution was kept at room temperature. After 
30mins, an aliquot solution was diluted with distilled water to get final 
concentration of 10µg/ml. The solution was scanned in the UV region and the 
maximum absorbance was recorded at 270nm.The same procedure was 
repeated for 60mins and 90mins time interval.  
Blank preparation 
100ml of 0.1M NaOH solution was taken in a 100ml volumetric flask, 
the solution was kept at room temperature, after 30 mins an aliquot solution 
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was diluted with distilled water to get final concentration. This is used as a 
blank. The procedure was repeated thrice .after the stipulated time. The 
absorption of the resulting solution showed maximum 270 nm against reagent 
blank treated in the same way. Three such determinations were made and the 
assay value was estimated. 
The percentage content of bulk was determined by following formula 
Percentage content = 
Sample absorbance ҳ Standard weight ҳ Dilution factor ҳ Purity of Standard ҳ100 
--------------------------------------------------------------------------------------------------- 
Standard absorbance x sample weight x100 
The amount of present was determined by following formula = 
Amount content= 
Sample absorbancex Standard weight ҳ Dilution factor ҳPurity of Standard ҳ Avg.wt tablets 
--------------------------------------------------------------------------------------------------- 
Standard absorbance x sample weight x100 
Percentage content of pyrazinamide was determined by following formula 
   Amount present 
Percentage content   = ------------------- 
       Label claim 
HYDROLYTIC DEGRADATION USING 0.1 M HCl 
Bulk preparation (stress) 
100mg of Pyrazinamide bulk was weighed and transferred to 
volumetric flask, dissolved 0.1M HCl to achieve a concentration of 1mg/ml. 
The solution was kept at room temperature. After 30mins, an aliquot solution 
was diluted with distilled water to get final concentration of 10 µg/ml. The 
solution was scanned in the UV region and the maximum absorbance was 
recorded at 270 nm. The same procedure was repeated for 60 min and 90mins 
time interval. 
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Sample preparation (stress) 
100mg equivalent of Pyrazinamide tablets were crushed weighed and 
transferred to volumetric flask, dissolved in 0.1M HCl to achieve a 
concentration of 1mg / ml. The solution was kept at room temperature. After 
30mins, an aliquot solution was diluted with distilled water to get f inal 
concentration of 10µg/ml. The solution was scanned in the UV region and the 
maximum absorbance was recorded at 270nm.The same procedure was 
repeated for 60mins and 90mins time interval.  
Blank preparation  
100 ml of 0.1M HCl solution was taken in a 100ml volumetric flask, 
the solution was kept at room temperature, after 30 min an aliquot solution 
was diluted with distilled water to get final concentration; this is used as a 
blank. The procedure was repeated thrice, after the stipulated time. The 
absorption of the resulting solution showed maximum 270nm against reagent 
blank treated in the same way. Three such determinations were made and the 
assay value was estimated. 
OXIDATIVE DEGRADATION USING 5%H2O2 
Bulk preparation (stress)  
100mg of Pyrazinamide bulk was weighed and transferred to 
volumetric flask, dissolved to 5% H2O2 achieves a concentration of 1mg/ml. 
The solution was kept at room temperature. After 30mins, an aliquot solution 
was diluted with distilled water to get final concentration of 10µg/ml. The 
solution was scanned in the UV region and the maximum absorbance was 
recorded at 270 nm same procedure was repeated for 60 mins and 90mins time 
interval. 
Sample preparation (stress) 
100mg equivalent of Pyrazinamide tablets were crushed weighed and 
transferred to volumetric flask, dissolved 5% H2O2 to achieve a concentration 
of 1mg /ml. The solution was kept at room temperature. After 30mins, an 
aliquot solution was diluted with distilled water to get final concentration of 
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10µg/ml .The solution was scanned in the UV region and the maximum 
absorbance was recorded at 270 nm. The same procedure was repeated for 
60mins and 90mins time interval.  
Blank preparation  
100ml of 5% H2O2 solution was taken in a 100ml volumetric flask. The 
solution was kept at room temperature. After 30mins an aliquot solution was 
diluted with distilled water to get final concentration. This is used as a blank. 
The procedure was repeated thrice .after the stipulated time. The absorption 
of the resulting solution showed maximum 270 nm against reagent blank 
treated in the same way. Three such determinations were made and the assay 
value was estimated. 
INTER DAY FORCED HYDROLYTIC DEGRADATION  
USING 0.1 M NaOH 
Bulk Preparation (stress) 
100mg of Pyrazinamide bulk was weighed and transferred to 
volumetric flask, dissolved 0.1M NaOH to achieve a concentration of 1mg/ml 
.The solution was kept at room temperature.  Then the next day (1
st
 day), an 
aliquot solution was diluted with distilled water to get final concentration of 
10µg/ ml. The solution was scanned in the UV region and the maximum 
absorbance was recorded at 270nm.The same procedure was repeated for 3
rd 
day and 5
th
 day time interval. The obtained spectrum is compared with 
standard spectrum. 
Sample Preparation (stress) 
100mg equivalent of Pyrazinamide tablets were crushed weighed and 
transferred to volumetric flask., dissolved 0.1M NaOH to achieve a 
concentration of 1mg/ml .The solution was kept at room temperature.  Then 
the next day (1
st
 day), an aliquot solution was diluted with distil led water to 
get final concentration of 10µg/ml. The solution was scanned in the UV 
region and the maximum absorbance was recorded at 270nm.The same 
procedure was repeated for 3
rd 
day and 5
th
 day time interval. The obtained 
spectrum is compared with standard spectrum. 
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Blank preparation  
100ml of 0.1M NaOH solutions was taken in a 100ml volumetric flask. 
The solution was kept at room temperature. The next day, an aliquot solution 
was diluted with distilled water to get final concentration. This procedure is 
repeated for 3
rd
 and 5
th
 day. 
The procedure was repeated thrice .After the stipulated time. The 
absorption of the resulting solution showed maximum 270nm against reagent 
blank treated in the same way. Three such determinations were made and the 
assay value was estimated. 
HYDROLYTIC DEGRADATION USING 0.1M HCl 
Bulk Preparation (stress) 
100mg of Pyrazinamide bulk was weighed and transferred to 
volumetric flask, dissolved 0.1M Hydrochloric acid to achieve a 
concentration of 1mg/ml .The solution was kept at room temperature.  Then 
the next day (1
st
 day), an aliquot solution was diluted with distilled water to 
get final concentration of 10µg/ml. The solution was scanned in the UV 
region and the maximum absorbance was recorded at 270nm.The same 
procedure was repeated for 3
rd 
day and 5
th
 day time interval. The obtained 
spectrum is compared with standard spectrum. 
Sample Preparation (stress) 
100mg equivalent of Pyrazinamide tablets were crushed weighed and 
transferred to volumetric flask, dissolved 0.1M Hydrochloric acid to achieve a 
concentration of 1mg/ml .The solution was kept at room temperature.  Then 
the next day (1
st
 day), an aliquot solution was diluted with distilled water to 
get final concentration of 10µg/ml. The solution was scanned in the UV 
region and the maximum absorbance was recorded at 270nm.The same 
procedure was repeated for 3
rd 
day and 5
th
 day time interval. The obtained 
spectrum is compared with standard spectrum. 
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Blank preparation  
100ml of 0.1M HCl solutions was taken in a 100ml volumetric flask . 
The solution was kept at room temperature the next day; an aliquot solution 
was diluted with distilled water to get final concentration. This procedure is 
repeated for 3
rd
 and 5
th
 day. 
The procedure was repeated thrice .After the stipulated time. The 
absorption of the resulting solution showed maximum 270nm against reagent 
blank treated in the same way. Three such determinations were made and the 
assay value was estimated. 
OXIDATIVE DEGRADATION USING 5% H2O2 
Bulk preparation (stress) 
100 mg of Pyrazinamide bulk was weighed and transferred to 
volumetric flask, dissolved to 5% H2O2 achieve a concentration of 1mg/ml 
.The solution was kept at room temperature. The next day (1
st
 day), an aliquot 
solution was diluted with distilled water to get final concentration of 
10µg/ml. The solution was scanned in the UV region and the maximum 
absorbance was recorded at 270 nm same procedure was repeated for 3
rd 
and 
5
th
 day time interval. 
Sample preparation (stress) 
100mg equivalent of Pyrazinamide tablets were crushed weighed and 
transferred to volumetric flask, dissolved 5% H2O2 to achieve a concentration 
of 1mg /ml. The solution was kept at room temperature. The next day (1
st
 
day), an aliquot solution was diluted with distilled water to get final 
concentration of 10µg/ml. The solution was scanned in the UV region and the 
maximum absorbance was recorded at 270nm. The same procedure was 
repeated for 3
rd
and 5
th
day time interval. 
Blank preparation  
100ml of 5% H2O2 solution was taken in a 100ml volumetric flask, the 
solution was kept at room temperature. The next day an aliquot solution was 
diluted with distilled water to get final concentration.  
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The procedure was repeated thrice .after the stipulated time. The 
absorption of the resulting solution showed maximum 270nm against reagent 
blank treated in the same way. Three such determinations were made and the 
assay value was estimated. 
THERMAL DEGRADATION  
Bulk Preparation (stress)  
1gm of Pyrazinamide bulk was weighed and transferred to a Petri dish. 
This Petri dish was placed in hot air oven at the temperature of 50ºC.The next 
day 100mg Pyrazinamide bulk was weighed from a Petri dish and transferred 
to 100ml volumetric flask. It was dissolved in water and the volume made up 
to 100ml .An aliquot solution was diluted with distilled  water to get final 
concentration of 10µg/ ml. The same procedure was repeated for 3
rd
 and 5
th
 
day. 
Sample Preparation (Stress) 
1gm of Pyrazinamide tablets were weighed and transferred to a Petri 
dish. This Petri dish was placed in hot air oven at the temperature of 50ºC.The 
next day 100mg equivalent of Pyrazinamide powder was weighed from a Petri 
dish and transferred to 100ml volumetric flask. It was dissolved in water and 
the volume made up to 100ml .An aliquot solution was diluted with distilled 
water to get final concentration of 10µg/ml. The same procedure was repeated 
for 3
rd
 and 5
th
 day. 
Blank Preparation 
Distilled water was used a blank 
PHOTOLYTIC DEGRADATION USING SUNLIGHT 
Bulk preparation (stress) 
1gm of Pyrazinamide bulk was weighed and transferred to a Petri dish. 
This Petri dish was placed under sunlight. The next day 100mg of 
Pyrazinamide bulk was weighed from a Petri dish and transferred to 100ml 
volumetric flask. It was dissolved in distilled water and the volume made up 
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to 100ml .An aliquot solution was diluted with distilled water to get final 
concentration of 10µg/ml. The same procedure was repeated for 3
rd
 and 5
th
 
day. 
Sample Preparation (Stress) 
1gm of Pyrazinamide tablets were weighed and transferred to a Petri 
dish. This Petri dish was placed under a sunlight .The next day 100mg 
equivalent of Pyrazinamide was weighed from a Petri dish and transferred to 
100ml volumetric flask. It was dissolved in distilled water and the volume 
made up to 100ml .An aliquot solution was diluted with distill ed water to get 
final concentration of 10µg/ml. The same procedure was repeated for 3
rd
 and 
5
th
 day. 
Blank Preparation 
Distilled water was used a blank 
INFRA RED SPECTROSCOPY 
Infrared spectroscopy is the spectroscopy that deals with the infrared 
region of the electromagnetic spectrum, which is light with a longer 
wavelength and lower frequency than visible light .The infrared portion of the 
electromagnetic spectrum is usually divided into three region; the near -,mid 
–and far-infra red, named for their relation to the visible spectrum. The IR 
region is mainly divided into two types  
Finger print region (1500-400cm
-1
) 
This will vary for every compound .In degradation studies this region 
can show a complete degradation of a sample otherwise no changes in the 
finger print region. 
Functional group region (4000-1500cm
-1
)  
This will give the peaks based on the functional group present in the 
compound. 
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In degradation studies it can shows the changes in functional groups. 
Standard can be compared with sample to detect the changes after the 
degradation
39
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IR spectroscopy is mainly used in thermal and photolytic degradation 
studies. 
Apparatus-Agilent Technologies 
All spectral measurement was made on (Rankem -IR) (Model No. 
Cary 630 FTIR KBr Press)  
Interday scheme of IR-study for bulk and formulation (Table-4) 
Degradation type Material (solid) Storage condition Sampling 
Normal Bulk  Room temperature  1,3,5days 
Sample  Room temperature 1,3,5days 
Photolysis Bulk   
Sunlight 
1,3,5days 
Sample  Sunlight 1,3,5days 
Thermal  
(Heating Chamber) 
Bulk  50ºC 1,3,5days 
Sample  50ºC 1,3,5days 
INTERDAY STUDY OF PYRAZINAMIDE BY IR 
General Procedure  
Pyrazinamide tablets were weighed and transferred into Petri dish. The 
first one was kept at room temperature, the second one was kept at chamber at 
50ºC and the third one was kept at sunlight .This was referred as 0 day. The 
bulk drug was weighed and transferred into 3different Petri dishes. The same 
procedure was repeated for bulk drug. 
Standard Preparation (Stress) 
The first day standard of the Pyrazinamide was weighed and reground 
with dry KBr Using agate mortar and pestle. The KBr were prepared by using 
KBr pellets press instrument .Then the percentage transmittance of the 
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standard was measured .The same procedure was repeated for 3
rd
 and 5
th
 day. 
The percentage transmittance was recorded in similar way.  
Bulk Preparation (stress) 
The first day standard of the Pyrazinamide was weighed and reground 
with dry KBr Using agate mortar and pestle. The KBr were prepared by using 
KBr pellets press instrument .Then the percentage transmittance of the 
standard was measured .The same procedure was repeated for 3
rd
 and 5
th
 day. 
The percentage transmittance was recorded in similar way.  
Sample preparation (stress) 
The next day (1
st
) day, required sample has been taken from the Petri 
dish. The required amount of bulk drug was reground with dry KBr using 
agate mortar and pestle. The discs were prepared by using KBr press 
instrument. Then the percentage transmittance of the bulk drug was measured. 
The spectrum obtained from degraded sample was compared with standard 
spectrum. The same procedure was repeated for 3
rd
 and 5
th
 day. The 
percentage transmittance was recorded in similar  
THERMAL DEGRADATION  
Bulk Preparation (stress) 
The next day (1
st
) day, the bulk from chamber was removed and the 
required quantity has been taken from the Petri dish. It was kept in the same 
place. The required amount bulk drug was reground with KBr agate mortar 
and pestle .The discs were prepared by using KBr press instrument. Then the 
percentage transmittance of the bulk drug was measured .The same procedure 
was repeated for 3
rd
 and 5
th
 day. The percentage transmittance was recorded 
in similar way. 
Sample Preparation (stress) 
Similar bulk procedure was followed 
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SUNLIGHT 
Bulk Preparation (stress)  
The next day (1
st
) day, the required quantity has been taken from the 
Petri dish .It was kept in the same place. The required amount bulk drug was 
reground with KBr agate mortar and pestle .The discs were prepared by using 
KBr press instrument. Then the percentage transmittance of the bulk drug was 
measured .The same procedure was repeated for 3
rd
 and 5
th
 day. The 
percentage transmittance was recorded in similar way.  
Sample Preparation (stress) 
Similar bulk procedure was followed 
UHPLC –ULTRA HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY 
Ultra High Performance Liquid Chromatography 
Ultra High Performance Liquid Chromatography is based on a 
modification to traditional liquid chromatographic systems that makes 
possible the use of increased operating pressures. Higher maximum operating 
pressures mean that packing material consisting of small (2µm) particle size 
can be used, by decreasing the particle size of packing material, the analyst 
can maximize the number of theoretical plates, making shorter column length 
possible. At the same time, by decreasing the particle size, the optimum range 
of mobile phase linear velocities is greatly expanded. As a result, higher 
linear velocities can be used without sacrificing separation quality. Both of 
these factors result in faster analytical run times and increased sample 
throughout. 
UHPLC instrument consists of reservoir of mobile phase, a pump, an 
injector, a separation column, and detector, compounds are separated by 
injecting a plug of the sample mixture into the column. The different 
compounds in the mixture pass through the column at different rates due to 
difference in their partitioning behavior between the mobile liquid and the 
stationary phase.
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Advantages of UHPLC 
Decreases run time and increases sensitivity.  
Provides the selectivity, and dynamic range of LC analysis  
Maintaining resolution performance 
Expands scope of multi residue methods 
Less solvent consumption.
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Intraday scheme UHPLC-Study of Bulk and Formulation (Table: 5) 
Degradation Experimental conditions Storage condition Sampling time 
 Control sample  
(No acid or base) 
Room Temperature 90 mins 
Hydrolysis 0.1M  HCl Room Temperature 90 mins 
0.1 M NaOH Room Temperature 90 mins 
Acid control (no API) Room Temperature 90 mins 
Base control (no API) Room Temperature 90 mins 
Oxidative 5% H2O2 Room Temperature 90 mins 
5% H2O2 (no API) Room Temperature 90 mins 
Interday scheme UHPLC-Study of Bulk and Formulation (Table: 6) 
Degradation Experimental conditions Storage condition Sampling time 
 Control sample  
(No acid or base) 
Room Temperature 3rd day 
Hydrolysis 
 
 
0.1 M HCl Room Temperature 3rd day 
0.1M NaOH Room Temperature 3rd day 
Acid control (no API) Room Temperature 3rd day 
Base control (no API) Room Temperature 3rd day 
Oxidative 5%H2O2 Room Temperature 3rd day 
5%H2O2(no API) Room Temperature 3rd day  
Thermal Heating chamber 50ºC 3rd day 
Photolysis Powder form sunlight 3rd day 
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REAGENTS AND CHEMICALS USED FOR UHPLC 
Acetonitrile 
Distilled Water 
Preparation of Phosphate Buffer (pH3.0) 
Dissolved 6.8045gm of Potassium di hydrogen phosphate and add 
1.844gm of Sodium hydroxide in 900 ml of water and pH adjusted to 3.0 with 
phosphoric acid and diluted to 1000ml with water. Then the solution was 
filtered through 0.45µ membrane filter. 
Preparation of Mobile Phase: 
A mixture of 100 volume of acetonitrile and 900 volume of phosphate 
buffer (100:900) respectively. The mobile phase was prepared and degassed. 
Mobile was used as diluent. 
Standard Preparation: 
80mg Pyrazinamide was transferred to 200ml volumetric flask and 
dissolved in distilled water and the volume made up to 200ml achieve a 
concentration of 4mg/ml. An aliquot solution was diluted with distilled water 
to get final concentration of 40µg/ml.  
METHODOLOGY FOR PYRAZINAMIDE IN BULK AND 
FORMULATION BY UHPLC  
System suitability solution: Transfer of 1ml hydrochloric acid to 
volumetric flask, dilute with standard preparation to volume mix. Keep the 
solution on a boiling water bath for 5 minutes and cooled. (1:4)  
Bulk Preparation (stress) 
80mg of Pyrazinamide was weighed, transferred to volumetric flask 
and dissolved in distilled water to achieve a concentration of 4mg/ml .An 
aliquot solution was diluted with water to get final concentration of 40 µg/ml.  
 
Materials and Methods 
College of Pharmacy, MMC, Chennai-3. Page No.34 
Sample Preparation (stress) 
80 mg equivalent of Pyrazinamide tablets were weighed, transferred to 
volumetric flask and dissolved in distilled water to achieve a concentration of 
4mg/ml .An aliquot solution was diluted with water to get final concentration 
of 40 µg /ml. Before the sample, bulk and standard solutions were filtered 
through a 0.45µm   membrane filter.  
Chromatographic Conditions: 
Column : C18, 25x4.6mm, (1.7µ.) 
Stationary phase : Silica 
Elution type :  Isocratic 
Mobile phase : 900:100(Phosphate buffer: acetonitrile) 
Detector :  PDA detector  
Flow rate : 1 ml/ minute 
λ max : 270nm 
Injection volume : 20µl 
Determination of Retention Time  
The mobile phase was injected first to determine the absence of any 
interference with the base line. The retention time was then determined by 
injecting 20µl of the standard in the column and the retention time was 
determined using 270 nm as the detection wavelength. The retention time was 
found to be 7 .0 to7.5 mins for pyrazinamide.  
Analysis of sample solution: 
The sample solution was diluted to get the required concentration and 
used for the quantification of Pyrazinamide 20 µl of the solution was injected 
into the column, retention time and peak area was determined.  
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Assay: 
20µl of Standard and sample solutions were injected separately with 
the flow rate of 1mL/minutes of the mobile phase containing acetonitrile and 
phosphate buffer of 100:900 Proportions.  
The amount of Pyrazinamide was calculated from the obtained 
chromatogram.  
         Spl. Area x Std Wt. x Dil .factor x Avg .Wt. x Purity of  Std  
Amount present= -----------------------------------------------------------------------  
       Std. Area   x Spl. Wt. x 100 
Percentage Content of Pyrazinamide  
 Amount to be present x 100 
Percentage Content=  -------------------------------- 
  Label claim 
INTRA DAY STUDY BY UHPLC OF BULK AND FORMULATION  
Hydrolytic Degradation Using 0.1M NaOH 
Standard Preparation 
80mg of Pyrazinamide was weighed and transferred to 200ml 
volumetric flask. It was dissolved in distilled water and the volume made up 
to 200ml to achieve a concentration of 4mg/ml. An aliquot solution was 
diluted with distilled water to get final concentration of 40µg/ml.  
Bulk Preparation (stress) 
80mg of Pyrazinamide was weighed and transferred to a 200ml 
volumetric flask. It was dissolved in 0.1M NaOH and the volume made up to 
200ml to achieve a concentration of 4mg/mL. After 90mins, an aliquot 
solution was diluted with mobile phase to get a concentration of 40µg/ml .The 
retention time and peak areas were determined by recording the 
chromatogram. 
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Sample Preparation (stress) 
 80mg equivalent of Pyrazinamide tablets were weighed and 
transferred to a 200ml volumetric flask. It was dissolved in 0.1M NaOH and 
the volume made up to 200ml to achieve a concentration of 4mg/ml. After 
90mins, an aliquot solution was diluted with mobile phase  to get a 
concentration of 40µg/ ml. The retention time and peak areas were determined 
by recording the chromatogram. 
Blank Preparation 
20ml of 0.1M NaOH was taken in a 200ml volumetric flask. After 
90mins, an aliquot solution was diluted with mobile phase , blank were 
determined by the chromatogram. Before solution was injected in to the 
column 
HYDROLYTIC DEGRADATION USING 0.1M HCl 
Bulk Preparation (stress) 
80mg of   Pyrazinamide was weighed and transferred to 200ml 
volumetric flask. It was dissolved in 0.1M HCl and volume made up to 200 
ml to achieve a concentration of 4mg/ml. after 90mins, an aliquot solution 
was diluted with mobile phase to get final concentration of 40µg/ml. The 
retention time and peak area were determined by recording the 
chromatograms. 
Sample Preparation (stress) 
80mg of   Pyrazinamide tablets were weighed and transferred to 200ml 
volumetric flask. It was dissolved in 0.1M HCl and volume made up to 200ml 
using to achieve a concentration of 4mg/ml. after 90mins, an aliquot solution 
was diluted with mobile phase to get final concentration of 40µg/ml. The 
retention time and peak area were determined by recording the chromatograms 
Blank Preparation 
20ml of  0.1M HCl was taken in a 200ml volumetric flask. After 
90mins, an aliquot solution was diluted with mobile phase, blank were 
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determined by the chromatogram. Before solution was injected in to the 
column. 
OXIDATIVE DEGRADATION USING 5% H2O2 
Bulk Preparation (stress)  
80mg of Pyrazinamide was weighed and transferred to a 200ml of 
volumetric flask. It was dissolve in 5% H2O2 and the volume made up to 
200ml using to achieve a concentration of 4mg/mL.After 90mins, an aliquot 
solution was diluted with mobile phase to get a concentration of 40µg/ml. The 
retention time and peak area were determined by recording the 
chromatograms. 
Sample Preparation (stress) 
80mg equivalent of Pyrazinamide tablets were weighed and transferred 
to a 200ml volumetric flask. It was dissolve in 5% H2O2 and the volume made 
up to 200ml to achieve a concentration of 4mg/ml. After 90mins, an aliquot 
solution was diluted with mobile phase to get a concentration of 40µg/ml .The 
retention time and peak area were determined by recording the 
chromatograms 
Blank Preparation 
20ml of 5% H2O2 was taken in a 100ml volumetric flask. After 90mins, 
an aliquot solution was diluted with mobile phase, blank were determined by 
the chromatogram. Before solution was injected in to the column 
INTER DAY STUDY BY UHPLC OF BULK AND FORMULATION 
HYDROLYTIC DEGRADATION USING 0.1M NaOH  
Standard Preparation 
80mg of Pyrazinamide was weighed and transferred to 200ml 
volumetric flask. It was dissolved in water and the volume made up to 200ml 
to achieve a concentration of 4mg/ml. An aliquot solution was diluted with 
distilled water to get final concentration 40µg/ml. Standard should be 
prepared daily. 
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Bulk Preparation (stress) 
80mg of Pyrazinamide was weighed and transferred to a 200ml 
volumetric flask. It was dissolved in 0.1M NaOH and the volume made up 
200ml to achieve a concentration of 4mg/ml. Then the third  day, an aliquot 
solution was diluted with mobile phase to get a concentration of 40µg/ml. The 
retention time and peak area were determined by recording the chromatogram.  
Sample Preparation (stress) 
80mg equivalent of Pyrazinamide tablets were weighed and transferred 
to a 200ml volumetric flask. It was dissolved in 0.1M NaOH and the volume 
made up 200 ml to achieve a concentration of 4mg/ml.  Then the third day, an 
aliquot solution was diluted with mobile phase to get a concentration of 
40µg/ml. The retention time and peak area were determined by recording the 
chromatogram. 
Blank Preparation 
20ml of 0.1M NaOH was taken in a 200ml volumetric flask. After 
90mins, an aliquot solution was diluted with mobile phase, blank were 
determined by the chromatogram. Before solution was injected in to the 
column. 
HYDROLYTIC DEGRADATION USING 0.1M HCI 
Bulk Preparation (stress)  
80mg of Pyrazinamide was weighed and transferred to 200ml 
volumetric flask. It was dissolved in 0.1M HCl and volume made up to 200ml 
to achieve a concentration of 4mg/ml. Then the third day, an aliquot solution 
was diluted with mobile phase to get final concentration of 40 µg/ml. The 
retention time and peak area were determined by recording the 
chromatograms. 
Sample Preparation (stress) 
80mg of Pyrazinamide tablets were weighed and transferred to 100ml 
volumetric flask. It was dissolved in 0.1M HCl and volume made up to 200ml 
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using to achieve a concentration of 4mg/ml. Then the third day, an aliquot 
solution was diluted with mobile phase to get final concentration of 40µg/ml. 
The retention time and peak area were determined by recording the 
chromatograms 
Blank Preparation 
20ml of 0.1M HCl was taken in a 100ml volumetric flask. After 
90mins, an aliquot solution was diluted with mobile phase blank were 
determined by the chromatogram. Before solution was injected in to the 
column. 
OXIDATIVE DEGRADATION USING 5% H2O2 
Bulk Preparation (stress)  
80mg of Pyrazinamide was weighed and transferred to a 200ml of 
volumetric flask. It was dissolved in 5% H2O2 and the volume made up to 
200ml to achieve a concentration of 4mg/ml. Then the third day, an aliquot 
solution was diluted with mobile phase to get a concentration of 40µg/ml. The 
retention time and peak area were determined by recording the chromatogram.  
Sample Preparation (stress) 
80mg equivalent of Pyrazinamide tablets were weighed and transferred 
to a 200ml volumetric flask. It was dissolved in 5% H2O2 and the volume 
made up to achieve a concentration of 4mg/ml. Then the third day, an aliquot 
solution was diluted with mobile phase to get a concentration of 40µg/ml. The 
retention time and peak area were determined by recording the 
chromatograms 
Blank Preparation 
20ml of 5% H2O2 was taken in a 100ml volumetric flask. After 90mins 
an aliquot solution was diluted with mobile phase blank were determined by 
the chromatogram. Before solution was injected in to the column.  
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THERMAL DEGRADATION  
Bulk Preparation (stress)  
1gm of Pyrazinamide bulk was weighed and transferred to a Petri dish. 
This Petri dish was placed in a hot air oven at the temperature of 50ºC. The 
third day, 80mg pyrazinamide bulk was weighed from a Petri dish and 
transferred to 200ml volumetric flask. An aliquot solution was diluted with 
mobile phase to get final concentration of 40µg/ml.  
Sample Preparation (stress) 
1gm of Pyrazinamide tablets were weighed and transferred to a Petri 
dish. This Petri was placed in a hot air oven at the temperature of 50ºC. The 
third day, 80mg Pyrazinamide bulk was weighed from a Petri dish and 
transferred to 200ml volumetric flask. An aliquot solution was diluted with 
mobile phase to get final concentration of 40µg/ml 
PHOTOLYTIC DEGRADATION USING SUNLIGHT 
Bulk Preparation (stress)  
1gm of Pyrazinamide bulk was weighed and transferred to a Petri dish. 
This Petri dish was placed under sunlight. The third day, 80mg Pyrazinamide 
bulk was weighed from a Petri dish and transferred to 200ml volumetric flask. 
An aliquot solution was diluted with mobile phase to get final concentration 
of 40 µg/ml. 
Sample Preparation (stress) 
1gm of Pyrazinamide bulk was weighed and transferred to a Petri dish. 
This Petri dish was placed under sunlight. The third day, 80mg Pyrazinamide 
bulk was weighed from a Petri dish and transferred to 200ml volumetric flask. 
An aliquot solution was diluted with mobile phase to get final concentration 
of 40µg/ml. 
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RESULTS AND DISCUSSION 
HYDROLYTIC DEGRADATION STUDY USING 0.1M SODIUM 
HYDROXIDE 
Hydrolytic degradation study was carried out as per the procedure 
given in the material and methods .The assay value of active ingredients was 
calculated using UV spectrophotometry.  
The respective UV- Spectrum and the values are given in Fig.1-4 and 
Table: 7, 8 
Fig.1 Overlay spectrum of Pyrazinamide Bulk with Standard in 0.1M NaOH  
   
30 Mins 90 Mins 
  
Fig.2 Overlay Spectrum of Pyrazinamide Sample with Standard in 0.1M NaOH 
30 Mins 60 Mins 
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Fig: 3 Overlay Spectrum of Pyrazinamide Bulk with Standard in 0.1 M NaOH    
 
1
st
 Day 5
th
 Day 
  
 
Fig: 4 Overlay Spectrum of Pyrazinamide Sample with Standard in 0.1 M NaOH     
1
st
 Day 5
th
 Day 
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Table 7: Intra Day Results of Hydrolytic Degradation Using 0.1M NaOH 
S.No. Drug Absorbance Standard Time 
1 Bulk 
0.4870 
0.6050 30 mins 0.4868 
0.4852 
2 Sample 
0.4824 
0.6050 30 mins 0.4772 
0.4614 
3 Bulk 
0.4587 
0.6050 60mins 0.4572 
0.4563 
4 Sample 
0.4441 
0.6050 60mins 0.4434 
0.4324 
5 Bulk 
0.4587 
0.6051 90mins 0.4527 
0.4535 
6 Sample 
0.4431 
0.6051 90mins 0.4223 
0.4200 
Table.7.1: Results Obtained From Hydrolytic Degradation 0.1M NaOH 
Stress Condition  
(Alkali Hydrolysis) 
Time 
Bulk Percentage 
Content (%) 
Sample 
Percentage 
Content (%) 
0.1 M Sodium 
Hydroxide 
30mins 80.38 78.29 
60mins 75.88 72.72 
90mins 75.20 70.82 
Each value is the mean of three determinations.  
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Table.8 Inter Day Result of Hydrolytic Degradation Using 0.1M NaOH 
S.No. Drug Absorbance Standard Time 
1 
Bulk 
0.4948 
0.6050 1st day 0.4925 
0.4923 
2 
Sample 
0.4724 
0.6051 1st  day 0.4722 
0.4732 
Table.8.1 Results Obtained From Hydrolytic Degradation 0.1 M NaOH 
Stress Condition  
(Alkali Hydrolysis) 
Time 
Bulk Percentage 
Content (%) 
Sample 
Percentage 
Content (%) 
0.1M Sodium 
Hydroxide 
 
1st Day 18.85 22.24 
3
rd
  day 0 0 
5th  day 
 
0 0 
GRAPHICAL REPRESENTATION OF INTRA DAY AND 
INTERDAY STUDY  (0.1M NaOH) 
Fig: 5 Assay values of Bulk and Samples at various time intervals 
Bulk Sample 
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Fig: 6 Assay values of Bulk and Sample at Various Time Intervals  
Bulk Sample 
  
The study results indicated that Pyrazinamide was unstable in alkali 
condition. Table 7 Shows the results of intraday degradation and the  assay 
values of standard and sample. 
In intraday investigation, the sample undergoes greater degradation.  
When compared to standard and it is clearly seen in assay values. The assay 
values of standard and sample were found to be 70.82% and 75.20% 
respectively at end of 90 mins degradation. The table 8.1 shows that the 
results of interday degradation.  In interday study, both  standard and sample 
have undergone maximum degradation on 1
st
 day. The assay values of 
standard and sample were found to be 18.85% and 22.24% repectively. 
Complete degradation was observed from 3
rd
 day onwards. 
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HYDROLYTIC DEGRADATION USING 0.1M 
HYDROCHLORIC ACID 
Hydrolytic degradation study was carried out as per the procedure 
given the material and methods .The assay value of active ingredients was 
calculated using UV spectrophotometry. The respective UV- spectrum and the 
values are given in Fig.7-10, Table.9-10. 
Fig: 7 Overlay spectrum of Pyrazinamide Bulk with Standard in 0.1M HCl  
30 Mins 60 Mins 
  
Fig: 8 Overlay spectrum of Pyrazinamide sample with Standard in 0.1M HCl 
30 Mins 90 Mins 
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Fig: 9 Overlay spectrum of Pyrazinamide Bulk with Standard in 0.1M HCl  
1
st
 Day 5
th
 Day 
  
 
 
Fig.10 Overlay spectrum of Pyrazinamide Sample with Standard in 0.1M HCl 
1
st
 Day 5
th
 Day 
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Table.9 INTRA DAY RESULTS OF HYDROLYTIC 
DEGRADATION USING 0.1M HCl 
S.No. Drug Absorbance Standard Time 
1 
Bulk 
0.4537 
0.6051 30 mins 0.4614 
0.4632 
2 
Sample 
0.4258 
0.6051 30 mins 0.4261 
0.4234 
3 
Bulk 
0.4513 
0.6045 60mins 0.4482 
0.4491 
4 
Sample 
0.4275 
0.6045 60mins 0.4251 
0.4202 
5 
Bulk 
0.4212 
0.6045 90mins 0.4110 
0.4131 
6 
Sample 
0.4240 
0.6045 90mins 0.4193 
0.4120 
Each value is the mean of three determinations 
Table.9.1 Results Obtained From Hydrolytic Degradation 0.1M HCl 
Stress Condition  
(Acid Hydrolysis) 
Time 
Bulk Percentage 
Content (%) 
Sample 
Percentage 
Content (%) 
0.1 M  Hydrochloric 
Acid 
30mins 75.90 70.20 
60mins 74.30 70.18 
90mins 68.61 69.16 
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Table.10 Inter Day Result Of Hydrolytic Degradation Using 0.1 M HCl 
S.No. Drug Absorbance Standard Time 
1 
Bulk 
0.4614 
0.6005 1st day 0.4582 
0.4583 
2 
Sample 
0.4464 
0.6005 1st day 0.4462 
0.4425 
Each value is the mean of three determinations 
Table.10.1 Results Obtained From Hydrolytic Degradation 0.1M HCl 
Stress Condition  
(Acid Hydrolysis) 
Time 
Bulk percentage 
content (%) 
Sample 
percentage 
Content (%) 
0.1 M Hydrochloric 
Acid 
 
1st Day 23.13 26.77 
3rd Day 0 0 
5th Day 0 0 
GRAPHCAL REPESENATION OF INTRA DAY AND INTERDAY 
STUDY (0.1M HCl) 
 Fig: 11 Assay values of Bulk and Sample various time intervals  
Bulk Sample 
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Fig: 12.Assay values of Bulk and Sample at various time intervals  
Bulk Sample 
  
Hydrolytic acid degradation indicated that Pyrazinamide was unstable 
in acid condition .In intraday degradation both the standard and sample 
exhibits meagre amount of degradation. However sample undergoes greater 
degradation than standard at 90mins. The assay values of standard and sample 
was found to be 68.61% and 69.16% respectively. Interday study complete 
degradation was observed on both standard and sample from 3
rd
 day on wards. 
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OXIDATIVE DEGRADATION USING 5% HYDROGEN PEROXIDE  
Oxidative degradation study was carried out as per the procedure given 
in the material and methods .The assay value of active ingredients was 
calculated using UV Spectrophotometry.  
The respective UV -spectrum and the values are given in Fig.13-16, 
Table-11-12 
Fig .13 Overlay spectrum of Pyrazinamide Bulk with Standard in 5% H 2O2 
30 Mins 60 Mins 
  
Fig.14 Overlay spectrum of Pyrazinamide Sample with Standard in 5% H 2O2 
30 Mins 90 Mins 
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Fig.15.Overlay spectrum of Pyrazinamide Bulk with Standard in 5% H 2O2 
1
st
 Day 5
th
 Day 
  
 
Fig.16.Overlay spectrum of Pyrazinamide Sample with Standard in 5%H2O2 
1
st
 Day 5
th
 Day 
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Table.11 Intra Day Results Of Oxidative Degradation Using 5% H2O2 
S. No. D rug Absorbance Standard Time 
1 
Bulk 
0.5282 
0.6051 30 mins 0.5321 
0.5242 
2 
Sample 
0.4663 
0.6051 30 mins 0.4632 
0.4544 
3 
Bulk 
0.4724 
0.6050 60mins 0.4712 
0.4744 
4 
Sample 
0.4598 
0.6050 60mins 0.4588 
0.4596 
5 
Bulk 
0.4591 
0.6053 90mins 0.4580 
0.4520 
6 
Sample 
0.4563 
0.6053 90mins 0.4453 
0.4363 
Table .11.1 Results Obtained from Oxidative Degradation 5% H2O2 
Stress 
Condition 
(Oxidation) 
Time 
Bulk Percentage content 
(%) 
Sample 
Percentage 
Content (%) 
 
5% H2O2 
 
30mins 87.30 76.24 
60mins 78.16 75.93 
90mins 75.4 73.71 
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Table .12 Inter Day Result Of Oxidative Degradation Using 5% H2O2 
S.No. D rug Absorbance Standard Time 
1 
Bulk 
0.4831 
0.5983 1st day 0.4821 
0.4820 
2 
Sample 
0.4851 
0.5983 1st day 0.4821 
0.4800 
 
Table .12.1Results Obtained From Oxidative Degradation 5% H2O2 
Stress Condition 
(Oxidation) 
Time 
Bulk Percentage 
Content (%) 
Sample 
Percentage 
Content (%) 
 
5% H2O2 
1
st
 Day 20.63 20.63 
3
rd
 Day 0 0 
5
th
 Day 0 0 
Fig: 17 .Assay Values of Bulk and Samples at Various Time 
Intervals (5%H2O2) 
Bulk Sample 
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Fig.18. Assay values of Bulk and samples at various time intervals 
Bulk Sample 
  
Oxidative degradation shows that Pyrazinamide was found to have a 
mild degradation in oxidative condition. In intraday analyses both sample and 
standard have undergone extensive degradation but when compared to 
standard, sample was largely degraded, at the end of 90mins degradation. In 
inter-day degradation study on 1
st
 day standard and sample undergone 
maximum degradation. The assay values of standard and sample were 20.63% 
and 20.63% respectively. Complete degradation was seen from 3
rd
 day 
onwards. 
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THERMAL DEGRADATION  
Pyrazinamide standard and sample kept in heating chamber at 
50˚C.The standard and samples powders were collected at different time 
intervals and the assay values were calculated by UV  
Spectroscopy. The respective UV- spectrum and the values are given 
Fig.19-20, Table.13. 
Fig .19. Overlay spectrum of Pyrazinamide Bulk with Standard 
1
st
 Day 5
th
 Day 
  
Fig.20. Overlay spectrum of Pyrazinamide Sample with Standard 
1
st
 Day 5
th
 Day 
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Table .13 Absorbance values for Thermal Degradation at 50˚C  
S. No. D rug Absorbance Standard Time 
1 
Bulk 
0.4626 
0.6050 1st day 0.4632 
0.4652 
2 
Sample 
0.4542 
0.6050 1st day 0.4538 
0.4533 
3 
Bulk 
0.4452 
0.6052 3rd day 0.4432 
0.4430 
4 
Sample 
0.4442 
0.6052 3rd day 0.4400 
0.4418 
5 
Bulk 
0.4428 
0.6052 5th day 0.4432 
0.4300 
6 
Sample 
0.4420 
0.6052 5th day 0.4400 
0.4312 
Table .13.1Results Obtained from Thermal Degradation at 50˚C  
Stress 
Condition 
(Thermal) 
Time 
Bulk percentage content 
(%) 
Sample 
percentage 
Content (%) 
 
50˚C 
1
st
 day 76.63 75.00 
3
rd
 day 73.35 73.03 
5
th
 day 72.48 72.32 
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GRAPHICAL REPRESENSATION OF THERMAL 
DEGRADATION STUDY   
Fig .21. Assay values of Bulk and Sample at various time intervals  
Bulk Sample 
  
In thermal degradation study small amount of degradation was 
observed up to 5
th
 day .It shows that bulk and formulation exhibit stability 
against temperature effect. At the end of the 5
th
 day the assay value bulk and 
sample were found to be 72.50% and 72.35% respectively.  
Results and Discussion 
College of Pharmacy, MMC, Chennai-3. Page No.59 
PHOTOLYTIC DEGRADATION USING SUNLIGHT 
Pyrazinamide standard and sample were kept in heating chamber  at 
50˚C.The standard and sample powders were collected at different time 
intervals and the assay value were calculated by UV Spectroscopy. The 
respective UV spectrum and the values are given Fig .22-23 Table-14. 
Fig.22. Overlay spectrum of pyrazinamide Bulk with Standard 
1
st
 Day 5
th
 Day 
  
Fig.23. Overlay spectrum of pyrazinamide sample with Standard 
1
st
 Day 5
th
 Day 
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Table. 14. Absorbance Values for Photolytic Degradation 
S. No. D rug Absorbance Standard Time 
1 
Bulk 
0.4681 
0.6050 1st day 0.4652 
0.4600 
2 
Sample 
0.4623 
  0.4612 
0.4620 
3 
Bulk 
0.4589 
0.6050 3rd day 0.4515 
0.4500 
4 
Sample 
0.4523 
  0.4452 
0.4442 
5 
Bulk 
0.4452 
0.6050 5th day 0.4432 
0.4358 
6 
Sample 
0.4389 
  0.4385 
0.4370 
Table.14.1 Results Obtained from Photolytic Degradation 
Stress 
Condition 
(Photolytic) 
Time 
Bulk percentage content 
(%) 
Sample 
percentage 
Content (%) 
 
Sunlight 
1st day 76.76 76.33 
3rd day 74.95 73.92 
5th day 72.95 72.41 
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GRAPHICAL REPRESENTATION OF PHOTOLYTIC 
DEGRADATION STUDY 
Fig .24. Assay values of bulk and samples at various time intervals  
Bulk Sample 
  
Photolytic degradation studies shows that sample underwent greater 
degradation compared to bulk. The assay value of standard and sample were 
found to be 72.95% and 72.41% at the end of 5
th
 day degradation. 
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2. IR STUDY OF BULK AND SAMPLES –UNDER STRESS 
AND NORMAL CONDITION: 
In inter day Thermal and Photolytic degradation the samples were kept 
in heating chamber and sunlight. The next day the samples and ground with 
KBr. Then the KBr pellets were formed using pellet pressing technique.IR 
Spectrum was taken for pellets .IR spectrum is given in  
Fig: 25-34, Table-15.   
Fig.25. STANDARD 
 
Fig.26. SAMPLE 
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THERMAL DEGRADATION 
Fig.27.Overlay IR Spectrum of Standard with Bulk in 1
st
 Day 
 
Fig .28. Overlay IR Spectrum of Standard with Bulk in 5
th
Day 
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Fig .29. Overlay IR Spectrum of Standard with Sample in 1
st
 Day 
 
Fig.30. Overlay IR Spectrum of Standard with Sample in 5
th 
Day 
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PHOTOLYTIC DEGRADATION USING SUNLIGHT 
Fig.31. Overlay IR Spectrum of Standard with Bulk in 1
st
 Day 
 
 
Fig.32. Overlay IR Spectrum of Standard with Bulk in 5
th
Day 
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Fig.33.Overlay IR Spectrum of Standard with Sample in 1
st
 Day 
 
 
Fig.34. Overlay IR Spectrum of Standard with Sample in 5
th
 Day 
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Table: 15 IR study of thermal and photolytic degradation 
Band Frequency 
(cm-1) 
Bulk Sample Result 
3412 N-H Stretching N-H Stretching No changes observed 
3161 C-H Stretching C-H Stretching No changes observed 
1713 C=O Stretching C=O Stretching No changes observed 
1610 C=N Stretching C=N Stretching No changes observed 
1579 C=C Stretching C=C Stretching No changes observed 
IR Spectroscopy study was performed for interday degradation. The 
study revealed that there are no changes in the functional group present in the 
pyrazinamide in bulk and formulations by KBr pellet technique, at the end of 
5
th
 day. 
 
UHPLC C-18 silica column was found to be suitable for pyrazinamide 
.The mobile phase used for assay was acetonitrile and phosphate buffer in the 
ratio 100:900.The flow rate maintained was1ml/min. The PDA detector was 
used in the wavelength of 270nm.The retention time was found to be 7 to 
7.5.The standard chromatogram is given Fig.35-44 Table-16. 
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UHPLC STUDY OF BULK AND SAMPLES –UNDER STRESS 
CONDITIONS 
Fig .35-44. STANDARD CHROMATOGRAM 
 
INTRA DAY UHPLC STUDY 
The chromatogram for intraday study are given in 
Fig.36. Chromatogram of Pyrazinamide Blank in 0.1M NaOH (90mins)  
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Fig.37. Chromatogram of Pyrazinamide Bulk in 0.1M NaOH (90mins) 
 
 
Fig.38. Chromatogram of Pyrazinamide Sample in 0.1M NaOH (90mins) 
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Fig. 39. Chromatogram for Pyrazinamide Blank in 0.1 M HCl (90mins) 
 
 
Fig. 40.Chromatogram for Pyrazinamide Bulk in 0.1 M HCl (90mins) 
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Fig.41. Chromatogram for Pyrazinamide Sample in 0.1 M HCl (90mins) 
 
 
Fig.42.Chromatogram for Pyrazinamide Blank in 5% H2O2 (90mins) 
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Fig.43.Chromatogram for Pyrazinamide Bulk in 5% H2O2 (90mins) 
 
 
Fig.44. Chromatogram for Pyrazinamide sample in 5% H2O2 (90mins) 
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Table-16 Intraday Results for Degradation 
Stress Condition Time Bulk Peak Area Sample Peak Area 
0.1M NaOH(Alkali) 90mins 1528.40 1481.25 
0.1M HCl (Acid) 90mins 1573.21 1551.55 
5% H2O2(Oxidation) 90mins 2387.02 2245.55 
 
Stress Condition Time 
Bulk Percentage 
Content (1%) 
Sample Percentage 
Content (1%) 
0.1M 
NaOH(Alkali) 
90mins 82.17 79.6 
0.1M HCl (Acid) 90mins 84.5 83.4 
5% H2O2 
(Oxidation) 
90mins 88.93 83.63 
Intraday UHPLC study indicates that pyrazinamide was undergone 
moderate degradation in hydrolytic and in oxidative study. It was observed 
that formulation was underwent greater degradation when compared to Bulk.  
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INTERDAY UHPLC STUDY 
Chromatogram for interday study are given in Fig: 45-53, Table-17 
Fig: 45.Chromatogram for Pyrazinamide Blank in 0.1M NaOH (3
rd 
day) 
 
 
Fig.46. Chromatogram for Pyrazinamide Bulk in 0.1M NaOH (3
rd 
day) 
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Fig.47. Chromatogram for Pyrazinamide Sample in 0.1M NaOH (3
rd 
day) 
 
Fig.48. Chromatogram for Pyrazinamide Blank in 0.1M HCl (3
rd 
day) 
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Fig.49. Chromatogram for Pyrazinamide Bulk in 0.1M HCl (3
rd 
day) 
 
 
Fig.50. Chromatogram for Pyrazinamide Sample in 0.1M HCl (3
rd 
day) 
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Fig.51. Chromatogram for Pyrazinamide Blank in 5 %H2O2 (3
rd 
day) 
 
Fig.52. Chromatogram for Pyrazinamide Bulk in 5% H2O2 (3
rd 
day) 
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Fig.53. Chromatogram for Pyrazinamide Sample in 5% H2O2 (3
rd 
day) 
 
Table-17 Interday Results for Degradation 
Stress Condition Time Bulk Peak Area Sample Peak Area 
0.1M NaOH(Alkali) 3rd Day - - 
0.1M HCl (Acid) 3rd Day - - 
5% H2O2(Oxidation) 3rd Day - - 
Thermal (50˚C) 3rd Day 1533.11 1547.31 
Sunlight(Photolysis) 3rd Day 1546.71 1480.21 
Table- Interday Results for Degradation 
Stress Condition Time 
Bulk Percentage 
Content (1%) 
Sample Percentage 
Content (1%) 
0.1M NaOH(Alkali) 3rd Day - - 
0.1M HCl(Acid) 3rd Day - - 
5% H2O2(Oxidation) 3rd Day - - 
Thermal (50˚C) 3rd Day 82.42 83.18 
Sunlight(photolysis) 3rd Day 83.15 79.58 
Complete degradation was observed 3
rd
 day hydrolytic and oxidative 
degradation. This indicates that Pyrazinamide is vulnerable both alkali, acid 
and 5%  H2O2. In Photolytic and thermal degradation shows only little amount 
of degradation. 
Summary and Conclusion 
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SUMMMARY AND CONCLUSION 
 The present study involves the stress induced stability studies such as 
alkali and acid hydrolytic degradation, oxidative degradation, thermal 
and photolytic degradation.  
 Degraded samples were quantified by UV and UHPLC method and the 
results of bulk and samples are compared with that of standard.  
 Changes in the functional group in degraded samples were identified 
by IR. It was found that no major changes in the functional group in 
the inter day investigation. 
 In all the methods used in this degradation study, sample undergoes 
greater degradation compared with that of standard.  
 An important feature in this study was that sample undergoes greater 
hydrolytic degradation (both acid & alkali) than other degradation 
methods used. This is because the amide group in pyrazinamide 
undergoes hydrolysis to form acid. There was only mild degradation in 
oxidation. 
FUTURE SCOPE 
 To develop and validate a stability indicating method  
 To determine the degradation pathways of drug substance and drug 
products. (e.g) during development phase.  
 To identify impurities related to  drug substance or excipients  
 To understand the drug molecular chemistry 
 To develop more stable formulations. 
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